Skip to main content

2017 - CCG Updates & Insights

    • How to Navigate the CTD2 Dashboard: Access to Translational Data
      , by The CTD^2 Dashboard Development Team

      The Cancer Target Discovery and Development (CTD2) Dashboard aims to provide easy exploration of data to non-computational scientists. Through an open-access web interface, users can view validated data and results assembled from multiple projects or CTD2 Centers.

      Continue Reading >

    • Hope for a Rare Disease Through TCGA: My Perspective as a Caregiver, Patient Advocate, and Physician
      , by Sara Selig, M.D., M.P.H.

      The founder of the Melanoma Research Foundation's Community United for Research and Education of Ocular Melanoma (CURE OM) initiative describes her journey from having a loved one diagnosed with a rare disease, to forming a patient advocacy group, to teaming up with The Cancer Genome Atlas in a collaborative research effort.

      Continue Reading >

    • CTD2: Bridging Genomics to Therapeutics
      , by Subhashini Jagu, Ph.D. & Freddie L. Pruitt, Ph.D.

      The Cancer Target Discovery and Development (CTD2) initiative was established by the National Cancer Institute (NCI) to bridge the gap between cancer genomics and precision oncology and has developed many approaches for identifying therapeutic targets, perturbagens, and biomarkers. CTD2 is currently exploring cancer heterogeneities and developing strategies to overcome treatment resistance.

      Continue Reading >

    • A Brief Tour of DAVE: The Genomic Data Commons Analysis Toolkit
      , by Zhining Wang, Ph.D.

      The Genomic Data Commons (GDC) gives a brief tour of DAVE: Data Analysis, Visualization, and Exploration Tools. GDC welcomes user questions and feedback to help build an accessible and valuable genomic data resource.

      Continue Reading >

    • TRACERx: Trailblazing Longitudinal Cancer Genomics
      , by Jean C. Zenklusen, M.S., Ph.D.

      The Cancer Genome Atlas (TCGA) has been analyzed in more than one thousand scientific publications and enabled countless discoveries, but mostly using cross-sectional studies. To study in depth how cancer evolves and progresses, NCI's Center for Cancer Genomics (CCG) is supporting the innovative, longitudinal study Tracking Non-Small-Cell Lung Cancer Evolution through Therapy (TRACERx).

      Continue Reading >

    • ROS1+ Cancer Patients Partner to Increase Research
      , by Janet Freeman-Daily, MS, Eng

      ROS1ders, a group of lung cancer patients who share a rare genetic abnormality involving the ROS1 gene, united to support each other and promote research. They formed the Global ROS1 Initiative, a collaboration between foundations, academic researchers, and industry that aims to improve outcomes for future patients.

      Continue Reading >

    • Researchers Design a Precise Library for CRISPR-Mediated Genetic Screens
      , by Amy E. Blum, M.A.

      Researchers in the Cancer Target Discovery and Development Network used machine learning to create improved CRISPR libraries for genomic studies. Their new libraries of single guide RNAs can be used to alter gene expression with greater sensitivity and specificity.

      Continue Reading >

    • Democratizing Access to CCG Data: Cancer Genomics Cloud Pilots
      , by Izumi Hinkson, Ph.D.

      Big data is essential to cancer research. Yet as we collect more cancer data, we limit the number of researchers who can participate. By enabling access to NCI data and computational resources in the cloud, the cloud pilots contribute to a cancer data ecosystem that enables diverse researchers to advance precision oncology.

      Continue Reading >

    • Functional Genomics Study Finds Druggable Target in KRAS-mutant Lung Cancer
      , by Amy E. Blum, M.A.

      A new study by the Cancer Target Discovery and Development Network identified XPO1 as a vulnerability specific to KRAS-mutant lung cancers that responds to available drugs. Paired with genomics-based patient selection, this finding could improve lung cancer care.

      Continue Reading >

    • TCGA to Complete its Final Analysis: the PanCanAtlas
      , by Amy E. Blum, M.A.

      TCGA’s data on all 33 cancer types will be integrated into its final analysis, called PanCanAtlas. PanCanAtlas will focus on the themes of cell-of-origin, oncogenic processes, and pathways.

      Continue Reading >

Featured Posts

Archive